Tumor inflamatorio miofibroblástico peritoneal. Respuesta favorable asociada a infliximab: Caso clínico

Myofibroblastic tumor (MIT) is characterized by the infiltration of different organs, most commonly the lungs, with nodular lesions composed of myofibroblasts and inflammatory cells, which can be identified by specific patterns in the immunohistochemical studies. When it involves the peritoneum it i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Grünholz,Daniela, Appiani,Franco, Abarca,Constanza, Manríquez,María, Pinilla,Jorge, Wainstein,Eduardo
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2015
Materias:	Anti-inflammatory agents Inflammatory neoplasms Infliximab Non-steroidal clooxygenase-2 inhibitors
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000700017
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872015000700017
record_format	dspace
spelling	oai:scielo:S0034-988720150007000172015-09-03Tumor inflamatorio miofibroblástico peritoneal. Respuesta favorable asociada a infliximab: Caso clínicoGrünholz,DanielaAppiani,FrancoAbarca,ConstanzaManríquez,MaríaPinilla,JorgeWainstein,Eduardo Anti-inflammatory agents Inflammatory neoplasms Infliximab Non-steroidal clooxygenase-2 inhibitors Myofibroblastic tumor (MIT) is characterized by the infiltration of different organs, most commonly the lungs, with nodular lesions composed of myofibroblasts and inflammatory cells, which can be identified by specific patterns in the immunohistochemical studies. When it involves the peritoneum it is difficult to eradicate, tends to relapse and it has an invasive behavior, requiring its differentiation from peritoneal carcinomatosis. Treatment may be surgical excision, the use of non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids. We report a 30 years old female with an unremarkable medical history, presenting with abdominal pain and progressive abdominal distention. A CT scan revealed multiple peritoneal nodular lesions. A surgical biopsy was reported as a myofibroblast and inflammatory cell infiltrate. Immunohistochemical staining was consistent with MIT. Given the extensive involvement of the peritoneum surgical therapy was not considered appropriate and treatment with NSAID and glucocorticoids was started. No response was observed after 6 months, therefore infliximab therapy was started. After 10 months of follow-up the patient is well, returned to normal life, ascites improved and resolved and CT scan showed partial regression or stabilization of the lesions.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.143 n.7 20152015-07-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000700017es10.4067/S0034-98872015000700017
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Anti-inflammatory agents Inflammatory neoplasms Infliximab Non-steroidal clooxygenase-2 inhibitors
spellingShingle	Anti-inflammatory agents Inflammatory neoplasms Infliximab Non-steroidal clooxygenase-2 inhibitors Grünholz,Daniela Appiani,Franco Abarca,Constanza Manríquez,María Pinilla,Jorge Wainstein,Eduardo Tumor inflamatorio miofibroblástico peritoneal. Respuesta favorable asociada a infliximab: Caso clínico
description	Myofibroblastic tumor (MIT) is characterized by the infiltration of different organs, most commonly the lungs, with nodular lesions composed of myofibroblasts and inflammatory cells, which can be identified by specific patterns in the immunohistochemical studies. When it involves the peritoneum it is difficult to eradicate, tends to relapse and it has an invasive behavior, requiring its differentiation from peritoneal carcinomatosis. Treatment may be surgical excision, the use of non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids. We report a 30 years old female with an unremarkable medical history, presenting with abdominal pain and progressive abdominal distention. A CT scan revealed multiple peritoneal nodular lesions. A surgical biopsy was reported as a myofibroblast and inflammatory cell infiltrate. Immunohistochemical staining was consistent with MIT. Given the extensive involvement of the peritoneum surgical therapy was not considered appropriate and treatment with NSAID and glucocorticoids was started. No response was observed after 6 months, therefore infliximab therapy was started. After 10 months of follow-up the patient is well, returned to normal life, ascites improved and resolved and CT scan showed partial regression or stabilization of the lesions.
author	Grünholz,Daniela Appiani,Franco Abarca,Constanza Manríquez,María Pinilla,Jorge Wainstein,Eduardo
author_facet	Grünholz,Daniela Appiani,Franco Abarca,Constanza Manríquez,María Pinilla,Jorge Wainstein,Eduardo
author_sort	Grünholz,Daniela
title	Tumor inflamatorio miofibroblástico peritoneal. Respuesta favorable asociada a infliximab: Caso clínico
title_short	Tumor inflamatorio miofibroblástico peritoneal. Respuesta favorable asociada a infliximab: Caso clínico
title_full	Tumor inflamatorio miofibroblástico peritoneal. Respuesta favorable asociada a infliximab: Caso clínico
title_fullStr	Tumor inflamatorio miofibroblástico peritoneal. Respuesta favorable asociada a infliximab: Caso clínico
title_full_unstemmed	Tumor inflamatorio miofibroblástico peritoneal. Respuesta favorable asociada a infliximab: Caso clínico
title_sort	tumor inflamatorio miofibroblástico peritoneal. respuesta favorable asociada a infliximab: caso clínico
publisher	Sociedad Médica de Santiago
publishDate	2015
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872015000700017
work_keys_str_mv	AT grunholzdaniela tumorinflamatoriomiofibroblasticoperitonealrespuestafavorableasociadaainfliximabcasoclinico AT appianifranco tumorinflamatoriomiofibroblasticoperitonealrespuestafavorableasociadaainfliximabcasoclinico AT abarcaconstanza tumorinflamatoriomiofibroblasticoperitonealrespuestafavorableasociadaainfliximabcasoclinico AT manriquezmaria tumorinflamatoriomiofibroblasticoperitonealrespuestafavorableasociadaainfliximabcasoclinico AT pinillajorge tumorinflamatoriomiofibroblasticoperitonealrespuestafavorableasociadaainfliximabcasoclinico AT wainsteineduardo tumorinflamatoriomiofibroblasticoperitonealrespuestafavorableasociadaainfliximabcasoclinico
_version_	1718436833694580736

Tumor inflamatorio miofibroblástico peritoneal. Respuesta favorable asociada a infliximab: Caso clínico

Ejemplares similares